Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Novel Evidence That the Mannan-Binding Lectin (MBL) Pathway of Complement Activation Plays a Pivotal Role in Triggering Mobilization of Hematopoietic Stem/Progenitor Cells By Activation of Both the Complement and Coagulation Cascades

Mateusz Adamiak, Malwina Suszynska, PhD, Ahmed Abdel-Latif, MD PhD, Ahmed Abdelbaset-Ismail, PhD, Janina Ratajczak, MD PhD, Magdalena Kucia, PhD, Mariusz Z Ratajczak, MD PhD

Blood (2016) 128 (22): 3371.

https://doi.org/10.1182/blood.V128.22.3371.3371

Published: 2016

Journal Articles

Evaluation of Bacteria-Mediated Potential "Bystander" Hemolysis of PNH RED CELLS I n Vitro : NO Evidence of Significant Complement Classical or Lectin Pathway-Mediated Hemolysis Induced by Microorganisms

Xuan Yuan, MD MSc, Guangwei Yang, PhD, Jane A Thanassi, Manuel D Galvan, PhD, Steven D Podos, PhD, Mingjun Huang, PhD, Robert A. Brodsky, MD

Blood (2016) 128 (22): 2431.

https://doi.org/10.1182/blood.V128.22.2431.2431

Published: 2016

Journal Articles

C5 Polymorphism in a Dutch Patient with Paroxysmal Nocturnal Hemoglobinuria (PNH) and No Asian Ancestry, Resistant to Eculizumab, but in Vitro Sensitive to Coversin

Saskia Langemeijer, MD PhD, Jun-Ichi Nishimura, MD PhD, Wynne Weston-Davies, Miles A Nunn, DPhil, Yuzuru Kanakura, MD PhD, Ian J Mackie, Petra Muus, MD PhD

Blood (2015) 126 (23): 1209.

https://doi.org/10.1182/blood.V126.23.1209.1209

Published: 2015

Journal Articles

Novel Evidence That Crosstalk Between Three Evolutionarily Ancient Proteolytic Enzyme Cascades (coagulation, fibrinolysis, and complement) Plays An Important Role In Mobilization Of Hematopoietic Stem/Progenitor Cells (HSPCs)

Sylwia Borkowska, MS, Malwina Suszynska, MS, Katarzyna Mierzejewska, PhD, Marta Budkowska, MS, Daria Salata, MS, Barbara Dolegowska, PhD, Janina Ratajczak, MD, PhD, Magdalena Kucia, Ph.D., Mariusz Z Ratajczak, MD, PhD

Blood (2013) 122 (21): 903.

https://doi.org/10.1182/blood.V122.21.903.903

Published: 2013

Journal Articles

Genetic Polymorphism of the Complement Receptor-1 ( CR1 ) Gene Correlates with the Clinical Response to Eculizumab of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Tommaso Rondelli, BS, Antonio M. Risitano, MD, PhD, Régis Peffault de Latour, MD, Benedetta Peruzzi, PhD, Ricci Patrizia, BS, Wilma Barcellini, MD, Anna Paola Iori, Carla Boschetti, MD, Veronica Valle, MD, Veronique Frémeaux-Bacchi, PhD, Maria De Angioletti, PhD, Gerard Socie, Lucio Luzzatto, MD, FRCP, FRCPath, Rosario Notaro, MD

Blood (2012) 120 (21): 983.

https://doi.org/10.1182/blood.V120.21.983.983

Published: 2012

Journal Articles

Thrombin generates previously unidentified C5 products that support the terminal complement activation pathway

Michael J. Krisinger, Verena Goebeler, Zhen Lu, Scott C. Meixner, Timothy Myles, Edward L. G. Pryzdial, Edward M. Conway

Blood (2012) 120 (8): 1717–1725.

https://doi.org/10.1182/blood-2012-02-412080

Published: 2012

Includes: Supplemental data

Journal Articles

Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway–mediated diseases

Masha Fridkis-Hareli, Michael Storek, Istvan Mazsaroff, Antonio M. Risitano, Ante S. Lundberg, Christopher J. Horvath, V. Michael Holers

Blood (2011) 118 (17): 4705–4713.

https://doi.org/10.1182/blood-2011-06-359646

Published: 2011

Includes: Supplemental data

Journal Articles

TT30, a Novel Human Complement Inhibitor in Development for Paroxysmal Nocturnal Hemoglobinuria and Other Hemolytic Disorders, Demonstrates Red Blood Cell Surface Targeting and Retention In a Model of Complement Alternative Pathway-Mediated Hemolysis

Masha Fridkis-Hareli, PhD, Michael Storek, PhD, Antonio M. Risitano, MD, PhD, Ante S. Lundberg, MD, Christopher J Horvath, DVM, MS, DACVP, V. Michael Holers, MD

Blood (2010) 116 (21): 638.

https://doi.org/10.1182/blood.V116.21.638.638

Published: 2010

Journal Articles

A Novel Approach to Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH): Both Hemolysis and C3 Deposition Are Blocked by a Monoclonal Antibody (mAb) Specific for the Alternative Pathway of Complement (APC) C3/C5 Convertase.

Ronald P Taylor, PhD, Margaret A Lindorfer, PhD, Andrew W Pawluczkowycz, MS, Charles J Parker, MD

Blood (2009) 114 (22): 157.

https://doi.org/10.1182/blood.V114.22.157.157

Published: 2009

Journal Articles

Factor H–related protein 1 (CFHR-1) inhibits complement C5 convertase activity and terminal complex formation

Stefan Heinen, Andrea Hartmann, Nadine Lauer, Ulrike Wiehl, Hans-Martin Dahse, Sylvia Schirmer, Katharina Gropp, Tina Enghardt, Reinhard Wallich, Steffi Hälbich, Michael Mihlan, Ursula Schlötzer-Schrehardt, Peter F. Zipfel, Christine Skerka

Blood (2009) 114 (12): 2439–2447.

https://doi.org/10.1182/blood-2009-02-205641

Published: 2009

Includes: Supplemental data

NARROW

Novel Evidence That the Mannan-Binding Lectin (MBL) Pathway of Complement Activation Plays a Pivotal Role in Triggering Mobilization of Hematopoietic Stem/Progenitor Cells By Activation of Both the Complement and Coagulation Cascades

Evaluation of Bacteria-Mediated Potential "Bystander" Hemolysis of PNH RED CELLS I n Vitro : NO Evidence of Significant Complement Classical or Lectin Pathway-Mediated Hemolysis Induced by Microorganisms

C5 Polymorphism in a Dutch Patient with Paroxysmal Nocturnal Hemoglobinuria (PNH) and No Asian Ancestry, Resistant to Eculizumab, but in Vitro Sensitive to Coversin

Novel Evidence That Crosstalk Between Three Evolutionarily Ancient Proteolytic Enzyme Cascades (coagulation, fibrinolysis, and complement) Plays An Important Role In Mobilization Of Hematopoietic Stem/Progenitor Cells (HSPCs)

Genetic Polymorphism of the Complement Receptor-1 ( CR1 ) Gene Correlates with the Clinical Response to Eculizumab of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Thrombin generates previously unidentified C5 products that support the terminal complement activation pathway

Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway–mediated diseases

TT30, a Novel Human Complement Inhibitor in Development for Paroxysmal Nocturnal Hemoglobinuria and Other Hemolytic Disorders, Demonstrates Red Blood Cell Surface Targeting and Retention In a Model of Complement Alternative Pathway-Mediated Hemolysis

A Novel Approach to Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH): Both Hemolysis and C3 Deposition Are Blocked by a Monoclonal Antibody (mAb) Specific for the Alternative Pathway of Complement (APC) C3/C5 Convertase.

Factor H–related protein 1 (CFHR-1) inhibits complement C5 convertase activity and terminal complex formation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only